The San Antonio Cancer Institute Flow Cytometry Core Facility is located within the University of Texas Health Science Center at San Antonio (UTHSCSA) Institutional Flow Cytometry Facility. The core includes a state-of-the-art rapid cell sorter (FACSstar Plus; 10,000 events/sec) and a new FACScalibur instrument for 3-4 color analysis. The facility is equipped with two workstations and two advanced printers (Tektronix). The Director of the combined facilities is Dr. Yair Gazitt (Medicine/Hematology, UTHSCSA), who has used flow cytometry for analysis and sorting since 1977 and has been the Director of the institutional Flow Cytometry Core Facility for the past five years. The core supports cell sorting and cloning of specific subpopulations of lymphocytes, various tumor cells, osteoclasts, osteoblasts, stem cells and kidney cells. This includes mouse models and human studies. Basic services offered to the San Antonio Cancer Institute consist of immunophenotyping (including leukemia, lymphoma breast cancer cells), DNA content and cell cycle analysis (including apoptosis analysis), cell sorting, multiparameter analysis (3-3 color), Ca++ fluxes, measurement of MDR-1 function and apoptosis. The facility has been instrumental in the success of several key established Cancer Center investigators and work is ongoing to develop new techniques in response to needs identified by SACI members. Protocols currently under development include sorting by DNA content and multiparameter cytokine quantitation using fluorescent microspheres (Becton Dickinson), a fluorescence based """"""""ELISA"""""""" assay.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ctrc Research Foundation
San Antonio
United States
Zip Code
Chalela, Patricia; Muñoz, Edgar; Gallion, Kipling J et al. (2018) Empowering Latina breast cancer patients to make informed decisions about clinical trials: a pilot study. Transl Behav Med 8:439-449
Chalela, P; Munoz, E; Inupakutika, D et al. (2018) Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial. Contemp Clin Trials Commun 12:109-115
Liu, Jinyou; Sareddy, Gangadhara R; Zhou, Mei et al. (2018) Differential Effects of Estrogen Receptor ? Isoforms on Glioblastoma Progression. Cancer Res 78:3176-3189
Weiner, Marc; Gelfond, Jon; Johnson-Pais, Teresa L et al. (2018) Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. Antimicrob Agents Chemother 62:
Van Skike, Candice E; Jahrling, Jordan B; Olson, Angela B et al. (2018) Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment. Am J Physiol Heart Circ Physiol 314:H693-H703
Chakravarthy, Divya; Muñoz, Amanda R; Su, Angel et al. (2018) Palmatine suppresses glutamine-mediated interaction between pancreatic cancer and stellate cells through simultaneous inhibition of survivin and COL1A1. Cancer Lett 419:103-115
Zhu, Haiyan; Gu, Xiang; Xia, Lu et al. (2018) A Novel TGF? Trap Blocks Chemotherapeutics-Induced TGF?1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers. Clin Cancer Res 24:2780-2793
Cooney, Jeffrey D; Lin, An-Ping; Jiang, Daifeng et al. (2018) Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K? in Mature B-cell Malignancies. Clin Cancer Res 24:1103-1113
Azpurua, Jorge; Mahoney, Rebekah E; Eaton, Benjamin A (2018) Transcriptomics of aged Drosophila motor neurons reveals a matrix metalloproteinase that impairs motor function. Aging Cell 17:
Bandyopadhyay, Abhik; Favours, Edward; Phelps, Doris A et al. (2018) Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer 65:

Showing the most recent 10 out of 989 publications